Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | CHKA | P35790 | 2/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 2/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | LSS | P48449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25108872 | 0.90 | KDM4E (0.43) | RORCKDM4EALDH1A1HRH3HTR1D | |
| SCHEMBL24514077 | 0.89 | MAPT (0.43) | RORCKDM4EALDH1A1HRH3HTR1D | |
| SCHEMBL22802982 | 0.84 | RORC (0.43) | RORCCHKAHTR1DHTR1BNCF1 | |
| SCHEMBL21655001 | 0.81 | HRH3 (0.45) | KDM4EALDH1A1LTA4HHRH3HTR1D | |
| SCHEMBL25111065 | 0.75 | MAPT (0.41) | RORCKDM4EALDH1A1HRH3HTR1D | |
| SCHEMBL9451684 | 0.73 | KDM4E (0.49) | RORCKDM4EALDH1A1LTA4HHRH3 | |
| SCHEMBL25110794 | 0.73 | KDM4E (0.43) | RORCKDM4EALDH1A1LTA4HHRH3 | |
| SCHEMBL25108491 | 0.73 | CHKA (0.40) | RORCCHKAHTR1DHTR1BNCF1 | |
| SCHEMBL25108893 | 0.73 | RORC (0.42) | RORCHRH3CHKANCF1 | |
| SCHEMBL25110409 | 0.71 | SIGMAR1 (0.45) | RORCKDM4EHRH3CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149549-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | RORC 2347/4885KDM4E 613/4885ALDH1A1 3473/4885 |
| US-20230072658-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCB1, SMARCE1 | RORC 2353/4885KDM4E 624/4885ALDH1A1 3736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.